These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 9806657)

  • 21. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
    Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
    Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
    Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B; Hansen HH; Høgdall C; Engelholm SA
    Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
    Kim HS; Kang SB; Seo SS; Han SS; Kim JW; Park NH; Kang SB; Lee HP; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():627-34. PubMed ID: 19723113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
    Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
    Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
    Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma.
    Strauss G; Lund B; Hansen M; Hansen HH
    Gynecol Oncol; 1997 Jul; 66(1):66-70. PubMed ID: 9234923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over].
    Delva R; Mege M; Gamelin E; Maillart P; Lortholary A; Guérin O; Pein F; Larra F
    Bull Cancer; 1996 Jan; 83(1):63-69. PubMed ID: 8672858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
    J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
    Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.